Antisense Oligonucleotide Suppression of Human IGF-1R Inhibits the Growth and Survival of in Vitro Cultured Epithelial Ovarian Cancer Cells

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2013 Oct 10

PMID 24103397

Citations 7

Authors

Jie Tang

Junjun Li

Guqing Zeng

Yanxiang Tang

Wenfang Tian

Jie He

J Philippe York

Xuefeng Xia

Affiliations

Soon will be listed here.

Abstract

Background: Preclinical evaluation of the anti-neoplastic activity of antisense oligonucleotide (AS) suppression of human insulin-like growth factor I receptor (IGF-IR) in human epithelial ovarian cancer (EOC).

Methods: Ovarian cancer cells from 36 patients with EOC were investigated under serum-free tissue culture conditions. IGF-I production was evaluated by standard ELISA. IGF-IR and phosphorylated IRS-1, AKT, and MAP kinase expression and protein levels were evaluated by immunohistochemistry and Western blotting. Cancer cell growth and proliferation assays were performed in triplicates using MTT assay. Apoptosis was evaluated by TUNNEL assay.

Results: All ovarian cancer tissue samples tested produced IGF-I and expressed IGF-IR, supporting the existence of an autocrine loop. Treatment of primary ovarian cancer cell lines with an IGF-1R AS inhibited growth and proliferation and decreased clonogenicity in soft agar assay. AS treatment was demonstrated to inhibit the expression of IGF-1R and decrease the concentration of phosphorylated IRS-1, AKT, and MAP kinase signaling protein downstream of the IGF-IR. We also observed that the IGF-1R AS sensitized cancer cell lines to cisplatin in vitro through the PI3K pathway.

Conclusions: IGF-IR enhances the proliferation and tumorigenicity of human ovarian cancer cells and inhibition of IGF-IR by AS oligonucleotide treatment potentiates the activity of cisplatin in vitro. Therefore, IGF-1R is a potential molecular target in ovarian cancer.

Citing Articles

Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines.

Almeida-Nunes D, Silva J, Nunes M, Silva P, Silvestre R, Dinis-Oliveira R Int J Mol Sci. 2024; 25(22).

PMID: 39596005 PMC: 11594113. DOI: 10.3390/ijms252211935.

FoxP3-miR-150-5p/3p suppresses ovarian tumorigenesis via an IGF1R/IRS1 pathway feedback loop.

Zhang Q, Zhou X, Wan M, Zeng X, Luo J, Xu Y Cell Death Dis. 2021; 12(3):275.

PMID: 33723215 PMC: 7961150. DOI: 10.1038/s41419-021-03554-6.

IGF1R Axis Inhibition Restores Dendritic Cell Antitumor Response in Ovarian Cancer.

Somri-Gannam L, Meisel-Sharon S, Hantisteanu S, Groisman G, Limonad O, Hallak M Transl Oncol. 2020; 13(8):100790.

PMID: 32428851 PMC: 7232112. DOI: 10.1016/j.tranon.2020.100790.

Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.

Camblin A, Tan G, Curley M, Yannatos I, Iadevaia S, Rimkunas V Sci Rep. 2019; 9(1):16832.

PMID: 31728045 PMC: 6856132. DOI: 10.1038/s41598-019-53322-y.

Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors.

Usset J, Raghavan R, Tyrer J, McGuire V, Sieh W, Webb P Cancer Epidemiol Biomarkers Prev. 2016; 25(5):780-90.

PMID: 26976855 PMC: 4873330. DOI: 10.1158/1055-9965.EPI-15-1039.

References

Virdee , Parone , Tolkovsky . Phosphorylation of the pro-apoptotic protein BAD on serine 155, a novel site, contributes to cell survival. Curr Biol. 2000; 10(23):R883. DOI: 10.1016/s0960-9822(00)00843-5. View

Yee D, Morales F, Hamilton T, Von Hoff D . Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res. 1991; 51(19):5107-12. View

Kalli K, Conover C . The insulin-like growth factor/insulin system in epithelial ovarian cancer. Front Biosci. 2003; 8:d714-22. DOI: 10.2741/1034. View

Sachdev D, Yee D . Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007; 6(1):1-12. DOI: 10.1158/1535-7163.MCT-06-0080. View

Jin Q, Esteva F . Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(4):485-98. DOI: 10.1007/s10911-008-9107-3. View

Burke F, Relf M, Negus R, Balkwill F . A cytokine profile of normal and malignant ovary. Cytokine. 1996; 8(7):578-85. DOI: 10.1006/cyto.1996.0077. View

Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman H, Kajstura J, Rubin R . The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res. 1995; 55(11):2463-9. View

Pollak M . Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol. 2008; 8(4):384-92. DOI: 10.1016/j.coph.2008.07.004. View

Resnicoff M, Ambrose D, Coppola D, Rubin R . Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest. 1993; 69(6):756-60. View

10.

Weiss J, Huang W, Rinaldi S, Fears T, Chatterjee N, Chia D . IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2007; 121(10):2267-73. DOI: 10.1002/ijc.22921. View

11.

Dong J, Demarest S, Sereno A, Tamraz S, Langley E, Doern A . Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther. 2010; 9(9):2593-604. DOI: 10.1158/1535-7163.MCT-09-1018. View

12.

Myers Jr M, Sun X, Cheatham B, Jachna B, Glasheen E, Backer J . IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. Endocrinology. 1993; 132(4):1421-30. DOI: 10.1210/endo.132.4.8384986. View

13.

Chien J, Aletti G, Bell D, Keeney G, Shridhar V, Hartmann L . Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer. J Cell Biochem. 2007; 102(5):1117-29. DOI: 10.1002/jcb.21552. View

14.

Belfiore A, Frasca F . IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2008; 13(4):381-406. DOI: 10.1007/s10911-008-9099-z. View

15.

MALKASIAN Jr G, Melton 3rd L, OBrien P, Greene M . Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol. 1984; 149(3):274-84. DOI: 10.1016/0002-9378(84)90227-8. View

16.

Pliarchopoulou K, Pectasides D . Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol. 2010; 79(1):17-23. DOI: 10.1016/j.critrevonc.2010.07.004. View

17.

del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G . Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997; 278(5338):687-9. DOI: 10.1126/science.278.5338.687. View

18.

Hadad S, Fleming S, Thompson A . Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 2008; 67(1):1-7. DOI: 10.1016/j.critrevonc.2008.01.007. View

19.

Harrington E, Bennett M, Fanidi A, Evan G . c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994; 13(14):3286-95. PMC: 395225. DOI: 10.1002/j.1460-2075.1994.tb06630.x. View

20.

Ozols R, Bookman M, Connolly D, Daly M, Godwin A, Schilder R . Focus on epithelial ovarian cancer. Cancer Cell. 2004; 5(1):19-24. DOI: 10.1016/s1535-6108(04)00002-9. View